Manganese-Based Nanotheranostics for Magnetic Resonance Imaging-Mediated Precise Cancer Management

Int J Nanomedicine. 2023 Oct 26:18:6077-6099. doi: 10.2147/IJN.S426311. eCollection 2023.

Abstract

Manganese (Mn)-based magnetic resonance imaging (MRI) has become a competitive imaging modality for cancer diagnosis due to its advantages of non-invasiveness, high resolution and excellent biocompatibility. In recent years, a variety of Mn contrast agents based on different material systems have been synthesized, and a series of multi-purpose Mn nanocomposites have also emerged, showing satisfactory relaxation efficiency and MRI performance thus possess the transformation and application value in MRI-synergized cancer diagnosis and treatment. This tutorial review starts from the classification and properties of Mn-based nanomaterials, and then summarizes various preparation and functionalization strategies of nanosized Mn contrast agents, especially focuses on the latest progress of Mn contrast agents in MRI-synergized precise cancer theranostics. In addition, present review also discusses the current clinical transformation obstacles such as unclear molecular mechanisms, potential nanotoxicity, and scale production constraints. This paper provides evidence-based recommendations about the future prospects of multifunctional nanoplatforms, as well as technical guidance and panoramic expectations for the design of clinically meaningful cancer management programs.

Keywords: magnetic resonance imaging; malignant tumor; manganese; precise diagnosis; targeted therapy.

Publication types

  • Review

MeSH terms

  • Contrast Media
  • Humans
  • Magnetic Resonance Imaging / methods
  • Manganese*
  • Neoplasms* / diagnostic imaging
  • Neoplasms* / therapy
  • Theranostic Nanomedicine / methods

Substances

  • Manganese
  • Contrast Media